seca Launches mBCA Alpha to Further Integrate Body Composition Screening into Primary Care
NEW YORK--(BUSINESS WIRE)-- seca, the global leader in medical measuring and weighing, today announced the latest addition to its line of advanced body composition analyzers, mBCA Alpha (Alpha), a compact, portable scanner specifically designed for use in a primary care setting. This new product further enhances seca's transformation from a measuring and weighing company to a modern technology-first solutions partner, making body composition screenings more accessible to all providers–not just specialists.
Utilizing validated bioelectrical impedance analysis (BIA), Alpha delivers a complete picture of a patient's body composition in just 24 seconds. seca's Alpha will assist providers in monitoring and flagging health measures such as early signs of excess adiposity, age-related muscle decline, and the total body impact of medications such as GLP-1s. The Alpha scanner is powered by the company's proprietary Analytics 125 platform, granting healthcare providers access to cloud-based reporting, seca's Treatment Tracker, and an app for patients that enables real-time data access.
Before the launch of a solution tailored to primary care providers, teams were forced to rely on methods like weight and body mass indexing (BMI) to understand their patients' risk for chronic conditions like obesity, diabetes, heart disease, and metabolic syndrome, which been criticized as an outdated, misleading, and even racially biased method of measuring health. Alpha's integration of body composition into primary care allows providers to gather more accurate and previously inaccessible insights into body fat, muscle mass, and visceral fat. This enables care teams to make more data-driven diagnoses, treatment, and long-term health monitoring decisions.
'We are witnessing a clinical transformation as clinicians and patients realize that BMI is no longer enough,' said Nina Crowley, PhD, RD, Director of Clinical Education and Partnerships at seca. 'As the industry shifts toward embracing a longitudinal care model that prioritizes precision, personalization, and prevention, we must ensure teams have innovative solutions that allow them to succeed in the care of their patients. Alpha was built to reflect how today's clinicians work–quickly, accurately, and intuitively.'
Alpha and the rest of seca's bioimpedance technology solutions are among the most clinically validated in the world, with 97 percent correlation to a whole-body MRI and 98 percent agreement with the gold-standard 4-compartment model for fat mass. By building its solutions on a foundation of scientific rigor, seca ensures that providers make decisions based on the highest-quality data available.
'As a primary care clinician and obesity medicine specialist, I'm a firm believer in the impact regular body composition screenings can have on patient care,' said Dr. Angela Fitch, Co-Founder and Chief Medical Officer of knownwell, a primary care company that uses seca's body composition scan for patients at its Boston and Dallas clinics. 'Rather than reference an outdated measurement like BMI, enabling patients to access body composition scans at their primary care appointments can help them engage in more meaningful conversations with their clinicians about their health goals and appropriate next steps to achieve them, resulting in better treatment outcomes.'
The launch of Alpha follows the company's introduction of Treatment Tracker, an industry-first solution that integrates a patient's treatment plan with their body composition results on a single platform to monitor clinical interventions, visualize changes, and modify treatment plans in real-time. For more information about seca and its suite of body composition solutions transforming care, please visit www.secambca.com.
About seca
seca, the global leader in medical body composition and weighing solutions, empowers healthcare providers with advanced technology that goes beyond weight and BMI to support comprehensive obesity care. With over 185 years of German engineering, seca sets the standard for precision, innovation, and reliability in medical measurement. Trusted worldwide in obesity medicine, bariatrics, and metabolic health, seca's scientifically validated body composition analyzers provide clinicians with key insights into fat mass, muscle mass, and hydration—helping optimize patient outcomes. seca's solutions integrate seamlessly into clinical workflows, ensuring accurate, data-driven care. www.secambca.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
Rocket Lab Completes Record Launch Turnaround From Launch Complex 1, Successfully Deploys 68 th Electron Mission
MAHIA, New Zealand--(BUSINESS WIRE)--Rocket Lab Corporation (Nasdaq: RKLB) ('Rocket Lab' or 'the Company'), a global leader in launch services and space systems, today successfully launched its 68th Electron rocket to deploy a single satellite to space for a confidential commercial customer. The mission was the second of two launches from the same launch site in less than 48 hours, a new launch record for the Company as it continues to deliver dedicated, repeatable and reliable access to space for satellite operators. The 'Symphony In The Stars' mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand on June 28 th (7:08 p.m./07:08 UTC) to deploy a single spacecraft to a 650km circular Earth orbit. The mission was the first of two dedicated launches for the new customer on Electron booked less than four months ago, with a second mission scheduled before the end of 2025. Rocket Lab has now completed four launches in June for commercial satellite constellation operators, underscoring Electron's consistent performance and rapid deployment capabilities as the world's leading small launcher: the 'Full Stream Ahead' mission on June 3 rd; 'The Mountain God Guards' mission on June 11 th; 'Get The Hawk Outta Here' launched on June 26 th UTC, and today's 'Symphony In The Stars' mission. Rocket Lab Founder and CEO, Sir Peter Beck, says: 'Electron has demonstrated once again that it is the gold standard for responsive and reliable space access for small satellites. The future of space is built on proven performance, and Electron continues to deliver against a stacked launch manifest this year. Congratulations to the team on achieving its fastest launch turnaround yet between two missions from Launch Complex 1. This launch was also a quick-turn mission to meet our customer's mission requirements, and we're looking forward to doing it again later this year.' 'Symphony In The Stars' was Rocket Lab's tenth Electron mission of 2025 and its 68th launch overall. With 100% mission success so far this year, Electron continues to deliver reliable deployment amid an increasing launch cadence and rapid contract-to-launch timelines. Launch images: About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered over 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words 'believe,' 'may,' 'will,' 'estimate,' 'potential,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'strategy,' 'future,' 'could,' 'would,' 'project,' 'plan,' 'target,' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'), accessible on the SEC's website at and the Investor Relations section of our website at which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Yahoo
2 days ago
- Yahoo
Traveling With Ozempic This Summer? Here's What Doctors Want You to Know
Traveling while taking a GLP-1 medication like Ozempic or Wegovy comes with its own set of challenges, and those challenges only multiply in the summer. Whether you're navigating a heat wave, spending hours on a plane or just trying to keep up with your summer routine, it's not always easy to stay consistent with your medication or manage potential side effects like nausea and fatigue. Hot weather alone can be a major obstacle, since most GLP-1 medications need to be kept refrigerated or at a stable temperature until use. Add in airport security, changing time zones and irregular meals, and it's easy to feel overwhelmed. But with the right planning, it's entirely possible to travel safely and comfortably while staying on track with your treatment. More from Flow Space 6 Expert Recommended Steps to Take Before the FDA Cracks Down on GLP-1 Drugs Here's what to know before you hit the road or friendly skies this summer. Traveling with GLP-1 medications requires some planning, especially during the summer months. When in room temperature conditions, opened pens can remain at room temperature for up to 28 days. However, if you are traveling by car in the summer heat, it is best to keep your medication in an insulated bag with cooling packs, Dr. Britta Reierson, a board-certified family physician and obesity medicine specialist at metabolic health company knownwell, tells Flow Space. 'Ensure that the packs don't directly touch the medication to avoid freezing,' she says. 'Store the medication out of direct sunlight and heat sources, and if you have overnight stops, use refrigeration whenever possible. You can even consider a portable mini-fridge that can go in the car for longer trips.' And what about while flying? Reierson says if your summer plans have you traveling by air, it is important to always carry your medication in your carry-on luggage to maintain consistent temperature and inform TSA officers that you are carrying injectable medication. Keep the medication in its original packaging with the prescription label. 'Also, use cooling packs to keep the medication cool during the flight,' she adds 'For international travel, I have provided my patients with a letter to present to TSA and customs if required. I recommend checking with state and country specific traveling with medication requirements prior to travel.' GLP-1s are known to cause side effects like nausea, an upset stomach, diarrhea and constipation. Not to mention, most GLP-1s are given via injection, which can sometimes cause pain at the site and might even require a band-aid. Because of this, Reierson recommends packing a 'medication go-bag.' To prepare, she suggests including the following: All prescription medications—enough to cover the entire trip, plus a couple extra days to cover for unexpected travel delays All injection supplies needed Over-the-counter medications, like pain relievers, antihistamines, antacids and anti-diarrheal medications First-aid supplies, such as bandaids, antiseptic and cleaning wipes, antibiotic ointment, sunscreen and insect repellent A printed list of your medications, dosings and a copy of health insurance/dental insurance card And while you may think you've packed and prepared everything needed, it's also important to start preparing your body in the days leading up to your travels. Dr. Shaline Rao, chief of cardiology and vice chair of the Department of Medicine Hospital Operations at NYU Langone Hospital—Long Island, recommends not starting a new medication or dose change in the days before travel as you may find yourself facing unexpected side effects. She says that with travel comes changes in hydration, frequency of meals, as well as the possibility of nausea or low appetite. If you have strong symptoms or are prone to these types of issues, talk to your physician before traveling for possible supportive care plans. 'For the majority of patients, making sure to stay hydrated, avoid extreme temperatures and eat small meals throughout the day should be sufficient,' she says. 'Making sure to take cues from your body is important. If you need time to rest, take the time you need.' If you forget a dosage during travel it will be easier to manage if you are traveling nationally, not abroad. You may consider transferring your prescription to a local branch of your national chain pharmacy, or contacting your doctor to call in a prescription to a nearby pharmacy. If you are abroad, you may need to find a local pharmacy or healthcare provider to prescribe the medication. 'In some countries you may be able to find GLP-1 medications for purchase without a prescription at a local pharmacy, however it is important to ensure you're buying from a reputable source to avoid counterfeit medications,' says Reierson. And if you fall off your dosing routine during travel? Rao says it is best to consult with your provider for guidance, but in general, you will be able to get back on a routine and be OK. 'If you do not have diabetes, then the consequence of a missed dose or delayed dose is likely low and you can work with your team to set up a resumed schedule,' she says. 'These medications are typically once a week, so the average traveler can get back on track quickly. This is why it is best to travel with extra supplies so as to minimize the stress of changes during travel.'
Business Wire
2 days ago
- Business Wire
Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit
BANGKOK--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2025 Invisalign ® Asia Pacific ('APAC') Summit held in Bangkok, Thailand, June 5 – 7, 2025. 'With more than 3 million Invisalign smiles across Asia Pacific, we know that this region sees some of the toughest clinical challenges in the field of dentistry,' said David Carr, Align executive vice president and managing director, APAC. 'The 2025 Invisalign Asia Pacific Summit underscores the importance of continued innovation and education. We are committed to working in partnership with doctors across the region in developing Invisalign treatment protocols that can help them transform smiles and change lives for even more patients.' Over three days, more than 2,000 doctors, practice team members, partners, and Align staff from across the region came together to explore the latest innovations in digital orthodontics and restorative dentistry. The summit featured over 60 expert speakers and more than 50 immersive breakout lectures and hands-on workshops, all designed to help doctors elevate clinical outcomes, streamline workflows, and grow their practices. Key topics covered include kids and teen, complex treatments, comprehensive dentistry and practice growth. 'This meeting provided us with a platform to connect with doctors across the full Asia Pacific region, encourage ongoing learning and sharing and showcase how our global innovations can support doctors in this market,' said Gigi Tsui, Align senior director, clinical, APAC. 'As we celebrate 20 million Invisalign smiles globally, including 3 million Invisalign smiles across the Asia Pacific region, it's critical that we continue to engage doctors for feedback and insights. This is fundamental to developing new innovations that meet the unique needs of doctors and patients across this region.' Attendees explored new developments across multiple interactive zones in the Innovation Hub, including: Kids and Teens: Featuring Invisalign First™, Invisalign® Palatal Expander System, and Invisalign® System with mandibular advancement featuring occlusal blocks ('MAOB'). ClinCheck® signature experience: Highlighting the 1-page Rx form (Flex Rx), preference templates, and ClinCheck ® Live Update. Comprehensive Dentistry: Showcasing iTero Lumina™ Pro dental imaging system, iTero™ intraoral scanner, Invisalign Smile Architect™, and Invisalign® Smile Video. Consumer & Branding: Demonstrating branding and tools to help doctors raise awareness of digital treatment options among patients of all ages. Clinical Excellence: Sharing clinical tools, evidence-based resources, education and insights available to doctors and staff. The summit also featured a Women Leadership session and provider recognition and lifetime achievement awardees. In addition to the core Asia Pacific Invisalign Summit, over 300 delegates across 78 universities also attended the Align APAC University Forum hosted at the renowned Chulalongkorn University in Bangkok. The forum served as a dynamic platform for cross-border collaboration and meaningful dialogue on how Align's evidence-based approach and cutting-edge innovations complements academic excellence and clinical training. Key highlights included keynote presentations by industry experts, interactive case-based discussions, resident showcases, and panels on integrating aligner therapy into university curriculum. The event also celebrated academic excellence with the APAC Case Challenge and Align research awards for APAC, while fostering peer-to-peer collaboration and inspiring the next generation of orthodontic leaders. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
